SDS Biotech K.K. reported consolidated and non-consolidated earnings results for the year ended March 31, 2017. For the year, the consolidated company reported net sales of ¥14,988 million compared to ¥21,345 million, operating income of ¥734 million compared to ¥2,022 million, ordinary income of ¥561 million compared to ¥1,680 million, net loss attributable to owners of parent of ¥203 million or ¥26.01 per share compared to net income attributable to owners of parent of ¥1,200 million ¥153.31 per share for the last year. Loss before income taxes and minority interests was ¥226.01 million compared to income before income taxes and minority interests ¥1,660.3 million, net cash used in operating activities was ¥5.2 million compared to ¥435.4 million, purchase of property, plant and equipment was ¥279.9 million compared to ¥263.7 million and purchase of intangible assets was ¥18.6 million compared to ¥57.6 million for the last year.

For the fiscal year 2017, the company announced dividend of ¥12.50 per share compared to ¥15.00 per share paid in last year.

For the second quarter of fiscal year 2018, the company expected to pay dividend of ¥12.50 per share.

For the fiscal year 2018, the company expected to pay dividend of ¥12.50 per share.

The company provided earnings guidance for the year ending March 31, 2018. For the year, the company expected net sales of ¥15,860 million, operating income of ¥1,440 million, ordinary income of ¥1,320 million, net income attributable to owners of parent of ¥630 million or ¥80.45 per share.

For the year, the non-consolidated company reported net sales of ¥12,491 million compared to ¥16,534 million, operating income of ¥1,263 million compared to ¥2,410 million, ordinary income of ¥1,316 million compared to ¥2,398 million, net loss attributable to owners of parent of ¥768 million or ¥98.16 per share compared to net income attributable to owners of parent of ¥1,608 million ¥205.42 per share for the last year.